$20 million payout for ex-CSL chief McNamee
Former CSL boss Brian McNamee left the top position at the blood products and vaccines supplier with pay and entitlements worth almost $20 million.
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter your SMS code' }}
A text message with your verification code was just sent to {{user.DayPhone}}
We cannot send you a code via SMS to {{user.DayPhone}}
Hi {{ user.FirstName }}, please provide your mobile number.
{{ content.trialHeading.replace('{0}', user.FirstName) }}
We'll send you a text message with a verification code to start your free {{ '0' == '1' ? 'Eureka Report' : 'Intelligent Investor' }} 15-day trial.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Eureka Report 15-day free trial
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Indepth analysis of ASX listed shares
- BUY, Hold and Sell Recommendations
- Ideas Lab
- Special Reports
- Alan Kohler’s Weekend Briefing
- Interviews with CEO’s & top influencers
- Money Cafe and Talking Finance
- Super Advice and Q&A with Ask Alan
Dr McNamee spent 23 years as chief executive of CSL and stepped down on June 30, after growing the company into a global bio-pharmaceutical company with an increased annual profit of $US1.22 billion in the 2012-13 financial year. He continues in an advisory capacity to the CSL board until October 15.
Dr McNamee was replaced by Paul Perreault, who, as president of CSL Behring, received $3.04 million in fiscal 2013.
CSL's annual report, released on Friday, shows that Dr McNamee's total remuneration for fiscal 2013 was $19.6 million compared with $7.99 million in the prior year. $7.88 million was received or available as cash in respect of 2013.
Dr McNamee's package included a cash salary and fees in 2013 of $3.41 million, up from $2.74 million.
He received a cash bonus of $2.38 million. His pay was boosted by a termination payment of $2.9 million, $7.75 million in performance rights and $1.77 million in performance options.
CSL said Dr McNamee's reported remuneration for 2013 included the full value of long-term incentives that were granted under the company's performance rights plan and reported between 2009 and 2012.
